Nektar Therapeutics Restructuring Costs and Asset Impairment Charges
Nektar Therapeutics (NKTR) reported Restructuring Costs and Asset Impairment Charges of $578.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:RestructuringCostsAndAssetImpairmentCharges · last filed 2026-08-14
- Nektar Therapeutics restructuring costs and asset impairment charges for the quarter ending 2026-06-30 was $578.00K, a 29.31% increase year-over-year.
- Nektar Therapeutics restructuring costs and asset impairment charges for the quarter ending 2026-03-31 was $796.00K, a 371.01% increase year-over-year.
- Nektar Therapeutics restructuring costs and asset impairment charges for the quarter ending 2025-12-31 was $8.57M, a 530.51% increase year-over-year.
- Nektar Therapeutics restructuring costs and asset impairment charges for the quarter ending 2025-09-30 was $140.00K, a 204.35% increase year-over-year.
- Nektar Therapeutics restructuring costs and asset impairment charges for fiscal 2025 was $9.33M, a 40.45% decline from fiscal 2024.
- Nektar Therapeutics restructuring costs and asset impairment charges for fiscal 2024 was $15.67M, a 69.84% decline from fiscal 2023.
- Nektar Therapeutics restructuring costs and asset impairment charges for fiscal 2023 was $51.96M, a 61.78% decline from fiscal 2022.
- Nektar Therapeutics restructuring costs and asset impairment charges for fiscal 2022 was $135.93M.
| Period end | Restructuring Costs and Asset Impairment Charges 3 month | Restructuring Costs and Asset Impairment Charges 6 month | Restructuring Costs and Asset Impairment Charges 9 month | Restructuring Costs and Asset Impairment Charges 12 month |
|---|---|---|---|---|
| 2026-06-30 | $578.00K 10-Q · filed 2026-08-14 | $1.37M 10-Q · filed 2026-08-14 | $9.95M derived: sum of 3 quarters · filed 2026-08-14 | $10.09M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $796.00K 10-Q · filed 2026-05-08 | $9.37M derived: sum of 2 quarters · filed 2026-05-08 | $9.51M derived: sum of 3 quarters · filed 2026-05-08 | $9.96M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $8.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $8.71M derived: sum of 2 quarters · filed 2026-03-13 | $9.16M derived: sum of 3 quarters · filed 2026-08-14 | $9.33M 10-K · filed 2026-03-13 |
| 2025-09-30 | $140.00K 10-Q · filed 2025-11-07 | $587.00K derived: sum of 2 quarters · filed 2026-08-14 | $756.00K 10-Q · filed 2025-11-07 | $2.12M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $447.00K 10-Q · filed 2026-08-14 | $616.00K 10-Q · filed 2026-08-14 | $1.98M derived: sum of 3 quarters · filed 2026-08-14 | $2.02M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $169.00K 10-Q · filed 2026-05-08 | $1.53M derived: sum of 2 quarters · filed 2026-05-08 | $1.57M derived: sum of 3 quarters · filed 2026-05-08 | $14.86M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $1.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $1.41M derived: sum of 2 quarters · filed 2026-03-13 | $14.70M derived: sum of 3 quarters · filed 2026-03-13 | $15.67M 10-K · filed 2026-03-13 |
| 2024-09-30 | $46.00K 10-Q · filed 2025-11-07 | $13.34M derived: sum of 2 quarters · filed 2025-11-07 | $14.31M 10-Q · filed 2025-11-07 | $17.16M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $13.29M 10-Q · filed 2025-08-08 | $14.26M 10-Q · filed 2025-08-08 | $17.11M derived: sum of 3 quarters · filed 2025-08-08 | $28.48M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $975.00K 10-Q · filed 2025-05-09 | $3.83M derived: sum of 2 quarters · filed 2025-05-09 | $15.19M derived: sum of 3 quarters · filed 2025-05-09 | $31.74M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $2.85M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | $14.21M derived: sum of 2 quarters · filed 2025-03-14 | $30.77M derived: sum of 3 quarters · filed 2025-03-14 | $51.96M 10-K · filed 2025-03-14 |
| 2023-09-30 | $11.36M 10-Q · filed 2024-11-08 | $27.91M derived: sum of 2 quarters · filed 2024-11-08 | $49.11M 10-Q · filed 2024-11-08 | $60.69M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $16.55M 10-Q · filed 2024-08-09 | $37.75M 10-Q · filed 2024-08-09 | $49.33M derived: sum of 3 quarters · filed 2024-08-09 | $66.16M derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | $21.19M 10-Q · filed 2024-05-10 | $32.77M derived: sum of 2 quarters · filed 2024-05-10 | $49.60M derived: sum of 3 quarters · filed 2024-05-10 | $155.65M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $11.58M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $28.41M derived: sum of 2 quarters · filed 2024-03-05 | $134.46M derived: sum of 3 quarters · filed 2024-03-05 | $135.93M 10-K · filed 2024-03-05 |
| 2022-09-30 | $16.83M 10-Q · filed 2023-11-08 | $122.88M derived: sum of 2 quarters · filed 2023-11-08 | $124.35M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $106.05M 10-Q · filed 2023-08-09 | $107.52M 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | $1.48M 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |